Boehringer Ingelheim in Diabetes

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In the treatment of diabetes, better treatments are still urgently needed and to be tested as to whether they actually improve patients' lives in the long run.
Based on its own research programmes, Boehringer Ingelheim has identified several drug candidates from multiple new drug classes with promising characteristics in diabetology. Two of these compounds from our own research are linagliptin, a DPP4 inhibitor, launched 2 years ago, and empagliflozin, an SGLT2 inhibitor, recently submitted for approval. In addition, we are collaborating with external research partners, exploring the causes of insulin-producing β-cell destruction to the cells and molecules triggering diabetic complications as well as investigating cell types that may contribute to the onset of obesity and diabetes.
Striving for a more holistic approach beyond drug treatment in diabetes, Boehringer Ingelheim is also concentrating on new business models and healthcare innovation.

Read the sponsor's message PDF (339 KB)


Extra navigation

Supported by

Boehringer Ingelheim

Extra navigation